title: Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study.
abstract: Amonafide, a benzisoquinoline-1,3-dione was administered to 38 patients with recurrent or metastatic, bidimensionally measurable endometrial cancer. There were 34 patients with no prior cytotoxic chemotherapy, performance status of 0-2, and normal bone marrow, renal, and hepatic function were eligible for response and toxicity evaluation. Amonafide, 300 mg/m2, was administered intravenously over 1 hour daily for 5 consecutive days. Courses were repeated every 21 days. The major grade 3 or 4 toxicities were hematologic with granulocytopenia in 18 patients (53%), thrombocytopenia in 6 patients (18%), and anemia in 8 patients (24%). Infectious complications occurred in 3 patients (9%). Other side effects included cardiac dysrhythmias, hypotension, pain and phlebitis at the site of injection, nausea, vomiting, and flu-like symptoms. The overall objective response rate was 6% (95% confidence interval of 1-20%); 2 patients had a complete response (6%), 9 patients had stable disease (26%) and 21 patients had progressive disease (62%). Two patients had insufficient follow-up for response determination and are assumed to be nonresponders. The median survival of the eligible patients was 8 months. With the toxicity observed and the low response rate, amonafide at this dose and schedule has no efficacy in the treatment of endometrial cancer.
authors.affiliation: Wayne State University School of Medicine, Detroit, Michigan.
authors.forename: V K
authors.initials: VK
authors.lastname: Malviya
authors.forename: P Y
authors.initials: PY
authors.lastname: Liu
authors.forename: R
authors.initials: R
authors.lastname: O'Toole
authors.forename: D S
authors.initials: DS
authors.lastname: Alberts
authors.forename: E
authors.initials: E
authors.lastname: Surwit
authors.forename: S
authors.initials: S
authors.lastname: Rosenoff
authors.forename: J H
authors.initials: JH
authors.lastname: Ward
authors.forename: A
authors.initials: A
authors.lastname: Yu
authors.forename: J
authors.initials: J
authors.lastname: O'Sullivan
authors.forename: J B
authors.initials: JB
authors.lastname: Craig
mesh_terms: D000225:Adenine; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007094:Imides / Q000009:adverse effects / Q000627:therapeutic use*; D007364:Intercalating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007546:Isoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D053644:Naphthalimides; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D063065:Organophosphonates; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007094:Imides; D007364:Intercalating Agents; D007546:Isoquinolines; D053644:Naphthalimides; D063065:Organophosphonates; C037020:amonafide; D000225:Adenine